Lv3
254 积分 2024-08-05 加入
Machine Learning Algorithms for Survival Analysis: Advantages, Disadvantages, and Examples
5个月前
已关闭
Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: Final results of the I-STOP study
6个月前
已完结
Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial
6个月前
已完结
Advances in the Basic Sciences in Thoracic Oncology in the Last 20 Years and Their Translational Impact
6个月前
已完结
190P: Real-world 5-year survival outcomes with durvalumab (D) after chemoradiotherapy (CRT) in unresectable, stage III NSCLC (urNSCLC): Final data extraction from PACIFIC-R
7个月前
已关闭
440P: Sexual health and its impact on quality of life of patients with lung cancer
7个月前
已关闭
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study
7个月前
已完结
Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study
7个月前
已完结
Non-small-cell lung cancer
7个月前
已完结
Advances in the Basic Sciences in Thoracic Oncology in the Last 20 Years and Their Translational Impact
7个月前
已完结
皖公网安备34019202002308
